The Hemostasis Apparatus in Pancreatic Cancer and Its Importance beyond Thrombosis
Abstract
:1. Introduction
2. Tissue Factor in Pancreatic Cancer
3. Angiogenesis in Pancreatic Cancer
3.1. Clotting Dependent Mechanism of Angiogenesis
3.2. Clotting Independent Mechanism of Angiogenesis
4. Factors That Can Enhance Thrombosis in PC
4.1. Extrinsic Factors
4.2. Intrinsic Factors
5. EGFR in Hemostasis and Angiogenesis
6. Thrombosis and Microparticles in Pancreatic Cancer
7. The Clinical Experience of Targeting Growth Factor Receptors in Pancreatic Cancer
8. Clinical Evidence of Benefit from Direct Interference with the Coagulation Apparatus
9. Conclusions
References
- Trousseau, A. Phlegmasia alba dolens. Clin. Med. Hotel. Dieu. Paris 1865, 3, 654–712. [Google Scholar]
- Stein, P.D.; Kayali, F.; Silbergleit, A.; Hull, R.D.; On, R.E.O. Incidence of pregnancy-associated venous thromboembolism. Ann. Internal. Med. 2006, 144, 453–454. [Google Scholar]
- Blom, J.W.; Doggen, C.J.M.; Osanto, S.; Rosendaal, F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005, 293, 715–722. [Google Scholar]
- Heit, J.A.; O'Fallon, W.M.; Petterson, T.M.; Lohse, C.M.; Silverstein, M.D.; Mohr, D.N.; Melton, L.J. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism - A population-based study. Arch. Intern. Med. 2002, 162, 1245–1248. [Google Scholar]
- Kirwan, C.C.; Nath, E.; Byrne, G.J.; McCollum, C.N. Prophylaxis for venous thromboembolism during treatment for cancer: Questionnaire survey. BMJ 2003, 327, 597–598. [Google Scholar]
- Kakkar, A.K.; Levine, M.; Pinedo, H.M.; Wolff, R.; Wong, J. Venous thrombosis in cancer patients: Insights from the FRONTLINE survey. Oncologist 2003, 8, 381–388. [Google Scholar]
- Sproul, E. Carcinoma and venous thrombosis: The frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am. J. Cancer 1938, 34, 566–585. [Google Scholar]
- Ogren, M.; Bergqvist, D.; Wahlander, K.; Eriksson, H.; Sternby, N.H. Trousseau'ssyndrome - what is the evidence? A population-based autopsy study. Thromb. Haemost 2006, 95, 541–545. [Google Scholar]
- Khorana, A.A.; Fine, R.L. Pancreatic cancer and thromboembolic disease. Lancet Oncol. 2004, 5, 655–663. [Google Scholar]
- Shah, M.M.; Saif, M.W. Pancreatic Cancer and Thrombosis. J. Pancreas 2010, 5, 331–333. [Google Scholar]
- Khorana, A.A.; Francis, C.W.; Menzies, K.E.; Wang, J.G.; Hyrien, O.; Hathcock, J.; Mackman, N.; Taubman, M.B. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J. Thromb. Haematol. 2008, 6, 1983–1985. [Google Scholar]
- Heit, J.A.; Mohr, D.N.; Silverstein, M.D.; Petterson, T.M.; O'Fallon, W.M.; Melton, L.J. Predictors of recurrence after deep vein thrombosis and pulmonary embolism - A population-based cohort study. Arch. Intern. Med. 2000, 160, 761–768. [Google Scholar]
- Wall, J.G.; Weiss, R.B.; Norton, L.; Perloff, M.; Rice, M.A.; Korzun, A.H.; Wood, W.C. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma-a cancer and leukemia group study. Am. J. Med. 1989, 87, 501–504. [Google Scholar]
- Moore, M.J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J.; Gallinger, S.; Au, H.; Ding, K.; Christy-Bittel, J.; Parulekar, W. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group NCIC-CTG. J. Clin. Oncol. 2005, 25, 1960–1966. [Google Scholar]
- Mandala, M.; Reni, M.; Cascinu, S.; Barni, S.; Floriani, I.; Cereda, S.; Berardi, R.; Mosconi, S.; Torri, V.; Labianca, R. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann. Oncol. 2007, 18, 1660–1665. [Google Scholar]
- Sgouros, J.; Maraveyas, A. Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncologica 2008, 47, 337–346. [Google Scholar]
- Maraveyas, A.; Johnson, M. Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? Brit. J. Cancer 2009, 100, 1837–1841. [Google Scholar]
- Nalluri, S.R.; Chu, D.; Keresztes, R.; Zhu, X.L.; Wu, S.H. Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients A Meta-analysis. JAMA 2008, 300, 2277–2285. [Google Scholar]
- Heit, J.A.; Silverstein, M.D.; Mohr, D.N.; Petterson, T.M.; O'Fallon, W.M.; Melton, L.J. Risk factors for deep vein thrombosis and pulmonary embolism - A population-based case-control study. Arch. Intern. Med. 2000, 160, 809–815. [Google Scholar]
- Bennett, C.L.; Silver, S.M.; Djulbegovic, B.; Samaras, A.T.; Blau, C.A.; Gleason, K.J.; Barnato, S.E.; Elverman, K.M.; Courtney, D.M.; McKoy, J.M.; Edwards, B.J.; Tigue, C.C.; Raisch, D.W.; Yarnold, P.R.; Dorr, D.A.; Kuzel, T.M.; Tallman, M.S.; Trifilio, S.M.; West, D.P.; Lai, S.Y.; Henke, M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008, 299, 914–924. [Google Scholar]
- Khorana, A.A.; Ahrendt, S.A.; Ryan, C.K.; Francis, C.W.; Hruban, R.H.; Hu, Y.C.; Hostetter, G.; Harvey, J.; Taubman, M.B. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin. Cancer Res. 2007, 13, 2870–2875. [Google Scholar]
- Spicer, E.K.; Horton, R.; Bloem, L.; Bach, R.; Williams, K.R.; Guha, A.; Kraus, J.; Lin, T.C.; Nemerson, Y.; Konigsberg, W.H. Isolation of CAD clones codingfor human-tissue factor-primary structure of the protein and. Proc. Natl. Acad. Sci. USA 1987, 84, 5148–5152. [Google Scholar]
- Gouaulthelimann, M.; Josso, F. Initiation invivo of blood coagulation-role of white blood-cells and tissue factor. Nouv. Presse. Med. 1979, 8, 3249–3253. [Google Scholar]
- Paborsky, L.R.; Tate, K.M.; Harris, R.J.; Yansura, D.G.; Band, L.; McCray, G.; Gorman, C.M.; Obrien, D.P.; Chang, J.Y.; Swartz, J.R.; Fung, V.P.; Thomas, J.N.; Vehar, G.A. Purification of recombinant human tissue factor. Biochemistry 1989, 28, 8072–8077. [Google Scholar]
- Nemerson, Y. Tissue factor and hemostasis. Blood 1988, 71, 1–8. [Google Scholar]
- Mechtcheriakova, D.; Wlachos, A.; Holzmuller, H.; Binder, B.R.; Hofer, E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Thromb. Haemost. 1999, 1827. [Google Scholar]
- Zhang, Y.M.; Deng, Y.H.; Luther, T.; Muller, M.; Ziegler, R.; Waldherr, R.; Stern, D.M.; Nawroth, P.P. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumour-cells in mice. J. Clin. Invest. 1994, 94, 1320–1327. [Google Scholar]
- Carmeliet, P.; Mackman, N.; Moons, L.; Luther, T.; Gressens, P.; VanVlaenderen, I.; Demunck, H.; Kasper, M.; Breier, G.; Evrard, P.; Muller, M.; Risau, W.; Edgington, T.; Collen, D. Role of tissue factor in embryonic blood vessel development. Nature 1996, 383, 73–75. [Google Scholar]
- Debaugnies, F.; Azerad, M.A.; Noubouossie, D.; Rozen, L.; Hemker, H.C.; Efira, A.; Demulder, A. Evaluation of the procoagulant activity in the plasma of cancer patients using a thrombin generation assay and an automated procoagulant assay. Thromb. Res. 2010, 125, S180–S180. [Google Scholar]
- Abe, K.; Shoji, M.; Chen, J.; Bierhaus, A.; Danave, I.; Micko, C.; Casper, K.; Dillehay, D.L.; Nawroth, P.P.; Rickles, F.R. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc. Natl. Acad. Sci. USA 1999, 96, 8663–8668. [Google Scholar]
- Kim, H.K.; Song, K.S.; Chung, J.H.; Lee, K.R.; Lee, S.N. Platelet microparticles induce angiogenesis in vitro. Brit. J. Haematol. 2004, 124, 376–384. [Google Scholar]
- Eilertsen, K.E.; Osterud, B. The role of blood cells and their microparticles in blood coagulation. Biocheme. Soc. Trans. 2005, 33, 418–422. [Google Scholar]
- Yu, J.L.; Rak, J.W. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J. Thromb. Haematol. 2004, 2, 2065–2067. [Google Scholar]
- Muller, I.; Klocke, A.; Alex, M.; Kotzsch, M.; Luther, T.; Morgenstern, E.; Zieseniss, S.; Zahler, S.; Preissner, K.; Engelmann, B. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J. 2003, 17, 476–478. [Google Scholar] [CrossRef]
- Ruf, W.; Fischer, E.G.; Huang, H.Y.; Miyagi, Y.; Ott, I.; Riewald, M.; Mueller, B.M. Diverse functions of protease receptor tissue factor in inflammation and metastasis. Immunol. Res. 2000, 21, 289–292. [Google Scholar]
- Wada, H.; Wakita, Y.; Shiku, H. Tissue factor expression in endothelial-cells in health and disease. Blood. Coagul. Fibrin. 1995, 6, S26–S31. [Google Scholar]
- Rak, J.; Milsom, C.; May, L.; Klement, P.; Yu, J. Tissue factor in cancer and angiogenesis: The molecular link between genetic tumor progression, tumor neovascularization, and cancer Coagulopathy. Sem. Thromb. Hemost. 2006, 32, 54–70. [Google Scholar]
- Bharthuar, A.; Khorana, A.A.; Hutson, A.; Wang, J.; Mackman, N.; Iyer, R.V. Association of elevated tissue factor (TF) with survival andthromboembolism (TE) in pancreaticobiliary cancers (PBC). J. Clin. Oncol. 2010, 28, 4126. [Google Scholar]
- Broze, G.J. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu. Rev. Med. 1995, 46, 103–112. [Google Scholar]
- Bajaj, M.S.; Kuppuswamy, M.N.; Saito, H.; Spitzer, S.G.; Bajaj, S.P. Cultured normal human hepatocytes do not synthesize lipoprotein-associated goagulation inhibitor-evidence that endothelium is the principal site of its synthesis. Proc. Natl. Acad. Sci. USA 1990, 87, 8869–8873. [Google Scholar]
- Sandset, P.M. Tissue factor pathway inhibitor (TFPI) - An update. Haemostasis 1996, 26, 154–165. [Google Scholar]
- Girard, T.J.; Warren, L.A.; Novotny, W.F.; Likert, K.M.; Brown, S.G.; Miletich, J.P.; Broze, G.J. Functionalsignificance of the kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989, 338, 518–520. [Google Scholar]
- Milsom, C.C.; Yu, J.L.; Mackman, N.; Micallef, J.; Anderson, G.M.; Guha, A.; Rak, J.W. Tissue Factor Regulation by Epidermal Growth Factor Receptor and Epithelial-to-Mesenchymal Transitions: Effect on Tumor Initiation and Angiogenesis. Cancer Res. 2008, 68, 10068–10076. [Google Scholar]
- Ettelaie, C.; Li, C.; Collier, M.E.W.; Pradier, A.; Frentzou, G.A.; Wood, C.G.; Chetter, I.C.; McCollum, P.T.; Bruckdorfer, K.R.; James, N.J. Differential functions of tissue factor in the trans-activation of Cell Signall pathways. Atherosclerosis 2007, 194, 88–101. [Google Scholar]
- Blum, S.; Issbruker, K.; Willuweit, A.; Hehlgans, S.; Lucerna, M.; Mechtcheriakova, D.; Walsh, K.; von der Ahe, D.; Hofer, E.; Clauss, M. An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression. J. Biol. Chem. 2001, 276, 33428–33434. [Google Scholar]
- Folkman, J. Angiogenesis inhibitors generated by tumors. Mol. Med. 1995, 1, 120–122. [Google Scholar]
- Lomberk, G. Angiogenesis. Pancreatology 2010, 10, 112–113. [Google Scholar]
- Gilbert, G.E.; Arena, A.A. Phosphatidylethanolamine induces high-affinity binding sites for factor-VIII on membranes containing phosphatidyl-L-serin. J. Biol. Chem. 1995, 270, 18500–18505. [Google Scholar]
- Falanga, A.; Rickles, F.R. Pathophysiology of the thrombophilic state in the cancer patient. Sem. Thromb. Hemost. 1999, 25, 173–182. [Google Scholar]
- Palumbo, J.S.; Kombrinck, K.W.; Drew, A.F.; Grimes, T.S.; Kiser, J.H.; Degen, J.L.; Bugge, T.H. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000, 96, 3302–3309. [Google Scholar]
- Ishihara, H.; Connolly, A.J.; Zeng, D.W.; Kahn, M.L.; Zheng, Y.W.; Timmons, C.; Tram, T.; Coughlin, S.R. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997, 386, 502–506. [Google Scholar]
- Kahn, M.L.; Zheng, Y.W.; Huang, W.; Bigornia, V.; Zeng, D.W.; Moff, S.; Farese, R.V.; Tam, C.; Coughlin, S.R. A dual thrombin receptor system for platelet activation. Nature 1998, 394, 690–694. [Google Scholar]
- Traynelis, S.F.; Trejo, J. Protease-activated receptor signaling: New roles and regulatory mechanisms. Curr. Opin. Hematol. 2007, 14, 230–235. [Google Scholar]
- Hu, L.; Lee, M.; Campbell, W.; Perez-Soler, R.; Karpatkin, S. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 2004, 104, 2746–2751. [Google Scholar]
- Mohle, R.; Green, D.; Moore, M.A.S.; Nachman, R.L.; Rafii, S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl. Acad. Sci. USA 1997, 94, 663–668. [Google Scholar]
- Nystedt, S.; Emilsson, K.; Larsson, A.K.; Strombeck, B.; Sundelin, J. Mollecular--cloning and functional expression of the gen encoding the human proteinase-activated receptor-2. Eur. J. Biochem. 1995, 232, 84–89. [Google Scholar]
- Camerer, E.; Huang, W.; Coughlin, S.R. Tissue factor-and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc. Natl. Acad. Sci. USA 2000, 97, 5255–5260. [Google Scholar]
- Camerer, E.; Gjernes, E.; Wiiger, M.; Pringle, S.; Prydz, H. Binding of Factor VIIa to tissue factor on keratinocytes induces gene expression. J. Biol. Chem. 2000, 275, 6580–6585. [Google Scholar]
- Albrektsen, T.; Sorensen, B.B.; Hjorto, G.M.; Fleckner, J.; Rao, L.V.M.; Petersen, L.C. Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells. J. Thromb. Haematol. 2007, 5, 1588–1597. [Google Scholar]
- Liu, Y.; Mueller, B.M. Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways. Biochem. Bioph. Res. 2006, 344, 1263–1270. [Google Scholar]
- Rudroff, C.; Schafberg, H.; Nowak, G.; Weinel, R.; Scheele, J.; Kaufmann, R. Characterization of functional thrombin receptors in human pancreatic tumor cells (MIA PACA-2). Pancreas 1998, 16, 189–194. [Google Scholar]
- Page-McCaw, A.; Ewald, A.J.; Werb, Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Molec. Cell Biol. 2007, 8, 221–233. [Google Scholar]
- Blom, J.W.; Vanderschoot, J.P.M.; Oostindier, M.J.; Osanto, S.; van der Meer, F.J.M.; Rosendaal, F.R. Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: Results of a record linkage study. J. Thromb. Haematol. 2006, 4, 529–535. [Google Scholar]
- Offord, R.; Lloyd, A.C.; Anderson, P.; Bearne, A. Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients. Pharmacy World Sci. 2004, 26, 214–220. [Google Scholar]
- Bergqvist, D.; Agnelli, G.; Cohen, A.T.; Eldor, A.; Nilsson, P.E.; Le Moigne-Amrani, A.; Dietrich-Neto, F.; Investigators, E.I. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. New Engl. J. Med. 2002, 346, 975–980. [Google Scholar]
- Mandala, M.; Falanga, A.; Piccioli, A.; Prandoni, P.; Pogliani, E.M.; Labianca, R.; Barni, S. Aiom Venous thromboembolism and cancer: Guidelines of the Italian Association of Med Oncol (AIOM). Critl. Rev. Oncol. Hematol. 2006, 59, 194–204. [Google Scholar]
- Yao, J.; Qian, C.J. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway. Med. Oncol. 2010, 27, 1017–1022. [Google Scholar]
- Wahrenbrock, M.; Borsig, L.; Le, D.; Varki, N.; Varki, A. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J. Clin. Invest. 2003, 112, 853–862. [Google Scholar]
- Chang, Y.T.; Chang, M.C.; Wei, S.C.; Tien, Y.W.; Hsu, C.; Liang, P.C.; Tsao, P.N.; Jan, I.S.; Wong, J.M. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas 2008, 37, 145–150. [Google Scholar]
- Pistol-Tanase, C.; Raducan, E.; Dima, S.O.; Albulescu, L.; Alina, I.; Marius, P.; Cruceru, L.M.; Codorean, E.; Neagu, T.M.; Popescu, I. Assessment of soluble angiogenic markers in pancreatic cancer. Biomark. Med. 2008, 2, 447–455. [Google Scholar]
- Niedergethmann, M.; Hildenbrand, R.; Wostbrock, B.; Hartel, M.; Sturm, J.W.; Richter, A.; Post, S. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002, 25, 122–129. [Google Scholar]
- Inoki, K.; Li, Y.; Zhu, T.Q.; Wu, J.; Guan, K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell. Biol. 2002, 4, 648–657. [Google Scholar]
- Yamanaka, Y.; Friess, H.; Kobrin, M.S.; Buchler, M.; Beger, H.G.; Korc, M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993, 13, 565–569. [Google Scholar]
- Heer, K.; Kumar, H.; Read, J.R.; Fox, J.N.; Monson, J.R.T.; Kerin, M.J. Serum vascular endothelial growth factor in breast cancer: Its relation with cancer type and estrogen receptor status. Clin. Cancer Res. 2001, 7, 3491–3494. [Google Scholar]
- Ikeda, N.; Adachi, M.; Taki, T.; Huang, C.; Hashida, H.; Takabayashi, A.; Sho, M.; Nakajima, Y.; Kanehiro, H.; Hisanaga, M.; Nakano, H.; Miyake, M. Prognostic significance of angiogenesis in human pancreatic cancer. Brit. J. Cancer 1999, 79, 1553–1563. [Google Scholar]
- Fujioka, S.; Yoshida, K.; Yanagisawa, S.; Kawakami, M.; Aoki, T.; Yamazaki, Y. Angiogenesis in pancreatic carcinoma - Thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival. Cancer 2001, 92, 1788–1797. [Google Scholar]
- Neutzner, M.; Lopez, T.; Feng, X.; Bergmann-Leitner, E.S.; Leitner, W.W.; Udey, M.C. MFG-E8/lactadherin promotes tumor growth in an angiogenesis-dependent transgenic mouse model of multistage carcinogenesis. Cancer Res. 2007, 67, 6777–6785. [Google Scholar]
- Herbst, R.S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. 2004, 59, 21–26. [Google Scholar]
- Suhara, T.; Mano, T.; Oliveira, B.E.; Walsh, K. Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP). Circ. Res. 2001, 89, 13–19. [Google Scholar]
- Gratton, J.P.; Morales-Ruiz, M.; Kureishi, Y.; Fulton, D.; Walsh, K.; Sessa, W.C. Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells. J. Biol. Chem. 2001, 276, 30359–30365. [Google Scholar]
- Nicholson, K.M.; Anderson, N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002, 14, 381–395. [Google Scholar]
- Yu, Y.; Sato, J.D. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. Cancer Res. 1999, 178, 235–246. [Google Scholar]
- Mahabeleshwar, G.H.; Feng, W.Y.; Phillips, D.R.; Byzova, T.V. Integrin signaling is critical for pathological angiogenesis. J. Exp. Med. 2006, 203, 2495–2507. [Google Scholar]
- Hood, J.D.; Frausto, R.; Kiosses, W.B.; Schwartz, M.A.; Cheresh, D.A. Differential alpha v integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J. Cell Biol. 2003, 162, 933–943. [Google Scholar]
- Yu, J.L.; May, L.; Lhotak, V.; Shahrzad, S.; Shirasawa, S.; Weitz, J.I.; Coomber, B.L.; Mackman, N.; Rak, J.W. Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis. Blood 2005, 105, 1734–1741. [Google Scholar]
- Friess, H.; Wang, L.; Zhu, Z.W.; Gerber, R.; Schroder, M.; Fukuda, A.; Zimmermann, A.; Korc, M.; Buchler, M.W. Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas. Ann. Surg. 1999, 230, 767–774. [Google Scholar]
- Dergham, S.T.; Dugan, M.C.; Arlauskas, P.; Du, W.; Vaitkevicius, V.K.; Crissman, J.D.; Sarkar, F.H. Relationship of family cancer history to the expression of p53, p21(WAF-1), HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma. Int. J. Pancreatol. 1997, 21, 225–234. [Google Scholar]
- Koka, V.; Potti, A.; Koch, M.; Fraiman, G.; Mehdi, S.; Levitt, R. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma. Anticancer Res. 2002, 22, 1593–1597. [Google Scholar]
- Citri, A.; Yarden, Y. EGF-ERBB signalling: Towards the systems level. Nat. Rev. Mol. Cell Biol. 2006, 7, 505–516. [Google Scholar]
- Petit, A.M.V.; Rak, J.; Hung, M.C.; Rockwell, P.; Goldstein, N.; Fendly, B.; Kerbel, R.S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo - Angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 1997, 151, 1523–1530. [Google Scholar]
- Viloria-Petit, A.; Miquerol, L.; Yu, J.L.; Gertsenstein, M.; Sheehan, C.; May, L.; Henkin, J.; Lobe, C.; Nagy, A.; Kerbel, R.S.; Rak, J. Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J. 2003, 22, 4091–4102. [Google Scholar]
- Yu, J.L.; Xing, R.; Milsom, C.; Rak, J. Modulation of the oncogene-dependent tissue factor expression by kinase suppressor of ras 1. Thromb. Res. 2010, 126, E6–E10. [Google Scholar]
- Zhang, J.J.; Zafrullah, M.; Yang, X.; Yin, X.L.; Zhang, Z.G.; Fuks, Z.; Kolesnick, R. Downregulation of KSR1 in pancreatic cancer xenografts by antisense oligonucleotide correlates with tumor drug uptake. Cancer Biol. Ther. 2008, 7, 1492–1497. [Google Scholar]
- Xing, H.R.; Cordon-Cardo, C.; Deng, X.Z.; Tong, W.; Campodonico, L.; Fuks, Z.; Kolesnick, R. Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. Nat. Med. 2003, 9, 1266–1268. [Google Scholar]
- Mostefai, H.A.; Agouni, A.; Carusio, N.; Mastronardi, M.L.; Heymes, C.; Henrion, D.; Andriantsitohaina, R.; Martinez, M.C. Phosphatidylinositol 3-kinase and xanthine oxidase regulate nitiric oxide and reactive oxygen species productions by apoptotic lymphocyte microparticles in endothelial cells. J. Immunol. 2008, 180, 5028–5035. [Google Scholar]
- Freyssinet, J.M. Cellular microparticles: What are they bad or good for? J. Thromb. Haematol. 2003, 1, 1655–1662. [Google Scholar]
- VanWijk, M.J.; VanBavel, E.; Sturk, A.; Nieuwland, R. Microparticles in cardiovascular diseases. Cardiovas. Res. 2003, 59, 277–287. [Google Scholar]
- Abid Hussein, M.N.; Meesters, E.W.; Osmanovic, N.; Romijn, F.P.H.T.M.; Nieuwland, R.; Sturk, A. Antigenic characterization of endothelial cell-derived microparticles and their detection ex vivo. J. Thromb. Haemost. 2003, 1, 2434–2443. [Google Scholar]
- Tilley, R.E.; Holscher, T.; Belani, R.; Nieva, J.; Mackman, N. Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb. Res. 2008, 122, 604–609. [Google Scholar]
- Del Conde, I.; Bharwani, L.D.; Dietzen, D.J.; Pendurthi, U.; Thiagarajan, P.; Lopez, J.A. Microvesicle-associated tissue factor and Trousseau's syndrome. J. Thromb. Haematol. 2007, 5, 70–74. [Google Scholar]
- Zwicker, J.I.; Liebman, H.A.; Neuberg, D.; Lacroix, R.; Bauer, K.A.; Furie, B.C.; Furie, B. Tumor-Derived Tissue Factor-Bearing Microparticles Are Associated With Venous Thromboembolic Events in Malignancy. Clin. Cancer Res. 2009, 15, 6830–6840. [Google Scholar]
- Giesen, P.L.A.; Rauch, U.; Bohrmann, B.; Kling, D.; Roque, M.; Fallon, J.T.; Badimon, J.J.; Himber, J.; Riederer, M.A.; Nemerson, Y. Blood-borne tissue factor: Another view of thrombosis. Proc. Natl. Acad. Sci. USA 1999, 96, 2311–2315. [Google Scholar]
- Tesselaar, M.E.T.; Romijn, F.; Van der Linden, I.K.; Prins, F.A.; Bertina, R.M.; Osanto, S. Microparticle-associated tissue factor activity: A link between cancer and thrombosis? J. Thromb. Haematol. 2007, 5, 520–527. [Google Scholar]
- Tesselaar, M.E.T.; Romijn, F.; van der Linden, I.K.; Bertina, R.M.; Osanto, S. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J. Thromb. Haematol. 2009, 7, 1421–1423. [Google Scholar]
- Zwicker, J.I.; Kos, C.A.; Johnston, K.A.; Liebman, H.A.; Furie, B.C.; Furie, B. Tissue factor-bearing microparticles are associated with an increased risk of venous thromboembolic events in cancer patients. Thromb. Res. 2007, 120, S143–S143. [Google Scholar]
- Falati, S.; Liu, Q.D.; Gross, P.; Merrill-Skoloff, G.; Chou, J.; Vandendries, E.; Celi, A.; Croce, K.; Furie, B.C.; Furie, B. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J. Exp. Med. 2003, 197, 1585–1598. [Google Scholar]
- Thomas, G.M.; Panicot-Dubois, L.; Lacroix, R.; Dignat-George, F.; Lombardo, D.; Dubois, C. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J. Exp. Med. 2009, 206, 1913–1927. [Google Scholar]
- del Conde, I.; Shrimpton, C.N.; Thiagarajan, P.; Lopez, J.A. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005, 106, 1604–1611. [Google Scholar]
- Ay, C.; Simanek, R.; Vormittag, R.; Dunkler, D.; Alguel, G.; Koder, S.; Kornek, G.; Marosi, C.; Wagner, O.; Zielinski, C.; Pabinger, I. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008, 112, 2703–2708. [Google Scholar]
- Kindler, H.L.; Ioka, T.; Richel, D.J.; Bennouna, J.; Letourneau, R.; Okusaka, T.; Bycott, P.; Ricart, A.D.; Kim, S.; Van Cutsem, E. A double-blinded, placebo-controlled, randomized, phase III study of axitinib (AG-013736; A) plus gemcitabine (G) vs. G plus placebo (P) in advanced pancreatic cancer (PC) patients (pts). EJC Suppl. 2009, 7, 361–362. [Google Scholar]
- Kindler, H.L.; Niedzwiecki, D.; Hollis, D.; Sutherland, S.; Schrag, D.; Hurwitz, H.; Innocenti, F.; Mulcahy, M.F.; O'Reilly, E.; Wozniak, T.F.; Picus, J.; Bhargava, P.; Mayer, R.J.; Schilsky, R.L.; Goldberg, R. M Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 2010, 28, 3617–3622. [Google Scholar]
- Burris, H.A.; Moore, M.J.; Andersen, J.; Green, M.R.; Rothenberg, M.L.; Madiano, M.R.; Cripps, M.C.; Portenoy, R.K.; Storniolo, A.M.; Tarassoff, P.; Nelson, R.; Dorr, F.A.; Stephens, C.D.; VanHoff, D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J. Clin. Oncol. 1997, 15, 2403–2413. [Google Scholar]
- Van Cutsem, E.; Vervenne, W.L.; Bennouna, J.; Humblet, Y.; Gill, S.; Van Laethem, J.L.; Verslype, C.; Scheithauer, W.; Cosaert, A.S.J.; Moore, M.J. Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer. J. Clin. Oncol. 2009, 27, 2231–2237. [Google Scholar]
- Philip, P.A.; Benedetti, J.; Corless, C.L.; Wong, R.; O'Reilly, E.M.; Flynn, P.J.; Rowland, K.M.; Atkins, J.N.; Mirtsching, B.C.; Rivkin, S.E.; Khorana, A.A.; Goldman, B.; Fenoglio-Preiser, C.M.; Abbruzzese, J.L.; Blanke, C.D. Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205. J. Clin. Oncol. 2010, 28, 3605–3610. [Google Scholar]
- Balzarotti, M.; Fontana, F.; Marras, C.; Boiardi, A.; Croci, D.; Ciusani, E.; Salmaggi, A. In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas. Oncol. Res. 2006, 16, 245–250. [Google Scholar]
- Yu, J.L.; Rak, J.W.; Klement, G.; Kerbel, R.S. Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. Cancer Res. 2002, 62, 1838–1846. [Google Scholar]
- Borsig, L. Antimetastatic activities of heparins and modified heparins. Experimental evidence. Thromb. Res. 2010, 125, S66–S71. [Google Scholar]
- Maraveyas, A.; Ettelaie, C.; Echrish, H.; Li, C.; Gardiner, E.; Greenman, J.; Madden, L.A. Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion. Blood Coagul. Fibrin. 2010, 21, 452–458. [Google Scholar]
- Maraveyas, A.; Waters, J.; Roy, R.; Propper, D.; Fyfe, D.; Lofts, F.; Bozas, G.; Gardiner, E.; Sgouros, J.; Wedgewood, K.R. Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): A multicentre, randomised phase IIB trial (the UK FRAGEM study). Thromb. Res. 2010, 125, S161–S161. [Google Scholar]
- Riess, H.; Pelzer, U.; Opitz, B.; Stauch, M.; Reitzig, P.; Hahnfeld, S. A prospective, randomised trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. J. Clin. Oncol. 2010, 28, 4033. [Google Scholar]
- Epstein, A.S.; Crosbie, C.; Gardos, S.; Soff, A.; Shah, M.A.; Kelsen, D.P.; O'Reilly, E.P. A single-institution (MSKCC) analysis of incidence andclinical outcomes in patients with thromboembolic events and exocrine pancreas cancer. J. Clin. Oncol. 2010, 28, 4062. [Google Scholar]
- Akl, EA; van Doormaal, FF; Barba, M; Kamath, G; Kim, SY; Kuipers, S; Middeldorp, S; Yosuico, VED; Dickinson, HO; Schunemann, H. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Systematic Rev. 2007, 3, Art. No.: CD006652. CD006652. [Google Scholar] [CrossRef] [Green Version]
© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Echrish, H.; Madden, L.A.; Greenman, J.; Maraveyas, A. The Hemostasis Apparatus in Pancreatic Cancer and Its Importance beyond Thrombosis. Cancers 2011, 3, 267-284. https://doi.org/10.3390/cancers3010267
Echrish H, Madden LA, Greenman J, Maraveyas A. The Hemostasis Apparatus in Pancreatic Cancer and Its Importance beyond Thrombosis. Cancers. 2011; 3(1):267-284. https://doi.org/10.3390/cancers3010267
Chicago/Turabian StyleEchrish, Hussein, Leigh A. Madden, John Greenman, and Anthony Maraveyas. 2011. "The Hemostasis Apparatus in Pancreatic Cancer and Its Importance beyond Thrombosis" Cancers 3, no. 1: 267-284. https://doi.org/10.3390/cancers3010267